BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27655638)

  • 1. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer.
    Li J; Huang J; Huang F; Jin Q; Zhu H; Wang X; Chen M
    Oncotarget; 2016 Nov; 7(45):73638-73650. PubMed ID: 27655638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
    Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
    Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
    Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
    Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
    Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
    PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
    Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
    J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
    Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
    Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
    Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
    Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.
    Shayanfar N; Zare-Mirzaie A; Mohammadpour M; Jafari E; Mehrtash A; Emtiazi N; Tajik F
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4253-4267. PubMed ID: 36063222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
    Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
    Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry.
    Byers R; Hornick JL; Tholouli E; Kutok J; Rodig SJ
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):37-40. PubMed ID: 22172803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
    Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
    Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
    Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.